A Phase 2 Randomized Trial of ELND005, Scyllo-Inositol, in Mild to Moderate Alzheimer Disease

Neurology - United States
doi 10.1212/wnl.0b013e3182309fa5
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Safety and Efficacy Results of a Phase II Randomized, Placebo-Controlled, Dose-Ranging Study of Elnd005 (Scyllo-Inositol) in Mild-To-Moderate Alzheimer's Disease

Alzheimer's and Dementia
Molecular NeuroscienceGerontologyHealth PolicyDevelopmental NeuroscienceMental HealthEpidemiologyGeriatricsCellularPsychiatryNeurology
2011English

A Phase II Trial of Huperzine a in Mild to Moderate Alzheimer Disease

Neurology
Neurology
2011English

Etanercept in Alzheimer Disease: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial

Neurology
Neurology
2015English

Intravenous Immunoglobulin for Treatment of Mild-To-Moderate Alzheimer's Disease: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Trial

The Lancet Neurology
Neurology
2013English

Ubiquinol Ameliorates Endothelial Dysfunction in Subjects With Mild-To-Moderate Dyslipidemia: A Randomized Clinical Trial

Nutrients
NutritionFood ScienceDietetics
2020English

Bapineuzumab for Mild to Moderate Alzheimer’s Disease: A Meta-Analysis of Randomized Controlled Trials

BMC Neurology
MedicineNeurology
2017English

Acupuncture for Adolescents With Mild-To-Moderate Myopia: Study Protocol for a Randomized Controlled Trial

Trials
MedicinePharmacology
2014English

MR Spectroscopy for Assessment of Memantine Treatment in Mild to Moderate Alzheimer Dementia

Journal of Alzheimer's Disease
GerontologyClinical PsychologyMental HealthPsychiatryGeriatricsMedicineNeuroscience
2011English

Journal Club: A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Treat Alzheimer Disease

Neurology
Neurology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy